Osteoporosis Therapeutics Market

Osteoporosis Therapeutics Market Analysis by Drug Class (Bisphosphonates, Selective Estrogen Inhibitor Modulators (SERM), Parathyroid Hormone Therapies), by Route of Administration (Oral, Injectable), by Region - Global Forecast 2022-2026

Analysis of Osteoporosis Therapeutics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Market Outlook of Osteoporosis Therapeutics

The global osteoporosis therapeutics market stands at a valuation of US$ 12.7 Bn currently, and is predicted to reach US$ 14.2 Bn by the end of 2026.

Consumption of osteoporosis therapeutic drugs is anticipated to increase at a CAGR of 2.9% from 2022 to 2026.

Report Attributes


Osteoporosis Therapeutics Market Size (2022)

US$ 12.7 Bn

Projected Year Value (2026F)

US$ 14.2 Bn

Global Market Growth Rate (2022-2026)

2.9% CAGR

United States Market Share (2022)


Key Companies Profiled

  • Allergan Plc.
  • Amgen Inc.
  • Chugai Pharmaceutical
  • Daiichi Sankyo Co. Ltd.
  • Egalet Corporation
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.

Demand for osteoporosis therapeutics in China is expected to progress at a higher than global average CAGR of 5.4% through 2026. Poor lifestyle choices and rising aging population have majorly influenced demand for osteoporosis treatment on a global scale.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Osteoporosis Therapeutics Demand Analysis (2017-2021) in Comparison to Market Growth Forecasts (2022-2026)

Incidence of osteoporosis has witnessed an exponential rise over the past few years and this trend is expected to be prevalent over the coming years as well. Osteoporosis is still one of the major diseases that go undiagnosed and untreated due to a lack of awareness about the condition.

Increasing geriatric population, rising awareness for osteoporosis, increasing availability of diagnostic procedures, growing sedentary lifestyle, and rapid development of novel treatments are major factors that guide the osteoporosis therapeutics market growth through 2026.

Longer time taken by regulatory bodies for approval of new osteoporosis drugs and side effects associated with prolonged use of the same are expected to have a restraining effect on the global osteoporosis therapeutics market potential.

Sales of osteoporosis drugs are projected to rise at a sluggish CAGR of 2.9% from 2022 to 2026.

Osteoporosis therapeutics market forecast by Fact.MR

What Will Favor Demand for Osteoporosis Drugs Going Ahead?

“Surging Aging Population to Boost Consumption of Osteoporosis Therapeutic Drugs”

The world is witnessing a significant rise in its aging population and this has shaped the healthcare industry with new opportunities. Osteoporosis is very common in the geriatric population and hence as the aging population increases, it drives a caseload of osteoporosis as well.

China and the United States are two prominent markets where the geriatric population is increasing and hence will be rewarding markets for osteoporosis drug vendors.

How is Osteoporosis Therapeutics Market Growth Being Hindered?

“Long Approval Times by Regulatory Authorities to Dent Osteoporosis Drug Sales”

All drugs have to undergo an approval procedure by respective regulatory authorities of their regions in order to be commercialized and available for patients and healthcare professionals.

The time taken for approval by these authorities for osteoporosis drugs is long and hence delays entry into the market and slows down osteoporosis therapeutics market potential.

“Lack of Awareness & Proper Diagnosis to Hinder Market Expansion”

General awareness about osteoporosis is very low compared to other prevalent diseases and this has hampered osteoporosis therapeutics market potential in the past and is expected to follow a similar trend over the forecast period as well.

Furthermore, the lack of diagnostic equipment for osteoporosis is also expected to constrain osteoporosis therapeutics market growth throughout the forecast period.

Which Regional Markets Should Osteoporosis Therapeutic Drug Suppliers Focus On?

“North America Expected to Account for Highest Osteoporosis Therapeutics Demand”

The North America osteoporosis therapeutics market is anticipated to have a bright outlook over the coming years and will hold a dominant market share in the global landscape.

Increasing sedentary lifestyles, rising instances of osteoporosis, the presence of developed healthcare infrastructure, and high healthcare spending potential are expected to be major factors influencing shipments of osteoporosis drugs through 2026.

The Europe osteoporosis therapeutics market is expected to hold a significant market share in the global landscape throughout the forecast period. Increasing spending on research and development activities are expected to prominently influence osteoporosis therapeutics market potential in this region.

South Asia and East Asia are predicted to provide lucrative opportunities for osteoporosis therapeutics market players. Rising awareness of osteoporosis, increasing healthcare expenditure, and the growing aging population in the aforementioned regions are expected to majorly influence osteoporosis therapeutics market growth.

Malaysia, India, and China are anticipated to be rewarding markets for osteoporosis drug suppliers.

Country-wise Insights

Why Should Osteoporosis Drug Manufacturers Focus on the U.S.?

“Increasing Incidence of Osteoporosis & High Healthcare Spending Provide Attractive Opportunities”

The U.S. is a highly lucrative market for healthcare products and technologies due to the presence of developed healthcare infrastructure in the nation. The nation has witnessed an increase in the aging population and this is a prominent factor that influences osteoporosis treatment demand in the U.S.

The U.S. accounts for a substantial market share of 41% in the global osteoporosis therapeutics industry landscape.

Will Osteoporosis Drug Suppliers Benefit in China?

“Surging Geriatric Population to Majorly Boost Consumption of Osteoporosis Drugs”

China has witnessed a noteworthy increase in the geriatric population and this will majorly guide osteoporosis drug shipments throughout the forecast period. Increasing healthcare expenditure and rising awareness about osteoporosis are expected to be other trends sculpting osteoporosis therapeutics market growth.

Osteoporosis therapeutic drug consumption is projected to rise at a CAGR of 5.4% from 2022 to 2026 in China.

Category-wise Insights

Which Route of Administration of Osteoporosis Drug Will Hold Major Market Share?

“Oral Route of Administration to Remain Most Popular”

Of the two major routes of administration, the oral segment is anticipated to account for a major market share in the global osteoporosis therapeutics landscape. This can be attributed to the high availability of oral osteoporosis drugs across the world.

However, the injectables segment is projected to see fast growth in sales over the next few years as demand for rapid action drugs increases on a global scale.

How Did the Osteoporosis Therapeutics Market Perform in 2020?

The world witnessed a pandemic of epic proportions in 2020 with the unprecedented outbreak of coronavirus infections and this led to major changes in the world economy. To contain the spread of coronavirus infections, multiple nations implemented total lockdowns and this led to the toppling of various markets.

Change of focus in the healthcare industry due to the pandemic led to a downfall in the osteoporosis therapeutics market growth as well. Lack of healthcare resources and lack of attention to the disease were two major factors slowing down the osteoporosis therapeutics market in 2020. Lack of diagnosis and closure of multiple sales channels also had a negative impact on the osteoporosis therapeutics market.

Osteoporosis drug sales are projected to see slow growth in the post-pandemic era and are anticipated to pick up pace as awareness of osteoporosis increases across the world. Increased focus on preventive healthcare in the post-pandemic world will also drive demand for osteoporosis prevention therapeutics.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Competitive Landscape

Osteoporosis drug manufacturers are increasing their investments in the research and development of novel drugs to fast-track new launches. Osteoporosis treatment injections are gaining popularity and market players are trying to launch these to advance their revenue potential in the global market.

  • In October 2021, Entera Bio, a leading biotechnology company, posted crucial data for its oral osteoporosis drug formulation trial that is in its mid-stage. The company moved ahead to phase 3 registration of this study.

Key Segments Covered in Osteoporosis Therapeutics Industry Research

  • by Drug Class :

    • Bisphosphonates
    • Selective Estrogen Inhibitor Modulators (SERM)
    • Parathyroid Hormone Therapies
    • Calcitonin
    • Rank Ligand Inhibitors
  • by Route of Administration :

    • Oral Osteoporosis Therapeutics
    • Injectable Osteoporosis Therapeutics
    • Other Routes of Administration
  • by Region :

    • North America
    • Latin America
    • Europe
    • East Asia
    • South Asia & Oceania
    • MEA

- FAQs -

What is the osteoporosis therapeutics market value at present?

The global osteoporosis therapeutics market is valued at US$ 12.7 Bn at present.

How big will the osteoporosis therapeutics market be by 2026?

The global market for osteoporosis therapeutics is slated to reach a valuation of US$ 14.2 Bn by the end of 2026.

How will demand for osteoporosis therapeutic drugs rise over the forecast period?

Consumption of osteoporosis therapeutic drugs is projected to expand at a sluggish CAGR 2.9% from 2022 to 2026.

Who are the key osteoporosis therapeutics market players mentioned in this research?

Key osteoporosis therapeutic drug manufacturers are Allergan Plc., Amgen Inc., Chugai Pharmaceutical, Daiichi Sankyo Co. Ltd., Egalet Corporation, and Eisai Co. Ltd.

What market share is held by the U.S?

The U.S. currently accounts for 41% of the global osteoporosis therapeutics market share.

At what rate will the China osteoporosis therapeutics market expand?

The China osteoporosis therapeutics market is anticipated to rise at a CAGR of 5.4% from 2022 to 2026.

Osteoporosis Therapeutics Market

Schedule a Call